The DOI matches its Crossref record; 359 of the 359 references it cites were found in a registry or an index.
Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: New trends in the development of miRNA therapeutic strategies in oncology (Review)
Open accessAbstract
MicroRNA (miRNA or miR) therapeutics in cancer are based on targeting or mimicking miRNAs involved in cancer onset, progression, angiogenesis, epithelial-mesenchymal transition and metastasis. Several studies conclusively have demonstrated that miRNAs are deeply involved in tumor onset and progression, either behaving as tumor-promoting miRNAs (oncomiRNAs and metastamiRNAs) or as tumor suppressor miRNAs. This review focuses on the most promising examples potentially leading to the development of anticancer, miRNA-based therapeutic protocols. The inhibition of miRNA activity can be readily achieved by the use of miRNA inhibitors and oligomers, including RNA, DNA and DNA analogues (miRNA antisense therapy), small molecule inhibitors, miRNA sponges or through miRNA masking. On the contrary, the enhancement of miRNA function (miRNA replacement therapy) can be achieved by the use of modified miRNA mimetics, such as plasmid or lentiviral vectors carrying miRNA sequences. Combination strategies have been recently developed based on the observation that i) the combined administration of different antagomiR molecules induces greater antitumor effects and ii) some anti-miR molecules can sensitize drug-resistant tumor cell lines to therapeutic drugs. In this review, we discuss two additional issues: i) the combination of miRNA replacement therapy with drug administration and ii) the combination of antagomiR and miRNA replacement therapy. One of the solid results emerging from different independent studies is that miRNA replacement therapy can enhance the antitumor effects of the antitumor drugs. The second important conclusion of the reviewed studies is that the combination of anti-miRNA and miRNA replacement strategies may lead to excellent results, in terms of antitumor effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
11 retracted
RETRACTED: A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis
Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szász, A. M., Wang, Z. C., Brock, J. E., Richardson, A. L., & Weinberg, R. A. (2009) · Cell · doi:10.1016/j.cell.2009.03.047 · Cited by 820
RetractedKong, W., He, L., Coppola, M., Guo, J., Esposito, N. N., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.101055 · Cited by 377
RetractedKrzeszinski, J. Y., Wei, W., Huynh, H., Jin, Z., Wang, X., Chang, T.-C., Xie, X.-J., He, L., Mangala, L. S., Lopez-Berestein, G., et al. (2014) · Nature · doi:10.1038/nature13375 · Cited by 303
RetractedGao, P., Xing, A.-Y., Zhou, G.-Y., Zhang, T.-G., Zhang, J.-P., Gao, C., Li, H., & Shi, D.-B. (2012) · Oncogene · doi:10.1038/onc.2012.61 · Cited by 150
RetractedYang, T., Lu, X., Wu, T., Ding, D.-D., Zhao, Z., Chen, G., Xie, X., Li, B., Wei, Y., Guo, L., et al. (2014) · Cancer Science · doi:10.1111/cas.12351 · Cited by 132
RetractedLiang, Z., Ahn, J. M., Guo, D., Votaw, J. R., & Shim, H. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0936-9 · Cited by 98
RetractedWang, L., Yao, J., Shi, X., Hu, L., Li, Z., Song, T., & Huang, C. Y. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-448 · Cited by 91
RetractedMicroRNA-33b Suppresses Migration and Invasion by Targeting c-Myc in Osteosarcoma Cells
Xu, N., Li, Z., Yu, Z., Yan, F., Liu, Y., Lu, X., & Yang, W.-L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115300 · Cited by 61
RetractedMicroRNA-493 Suppresses Tumor Growth, Invasion and Metastasis of Lung Cancer by Regulating E2F1
Gu, Y., Cheng, Y., Song, Y., Zhang, Z., Deng, M., Wang, C., Zheng, G., & He, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102602 · Cited by 58
RetractedmiR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6
Wen, Q., Zhao, J., Bai, L., WANG, T., Zhang, H., & Ma, Q. (2015) · Oncology Reports · doi:10.3892/or.2015.4165 · Cited by 33
Retracted
Cited by
RNAi therapeutic and its innovative biotechnological evolution
Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 286
Improved Loading of Plasma-Derived Extracellular Vesicles to Encapsulate Antitumor miRNAs
Pomatto, M. A. C., Bussolati, B., D’Antico, S., Ghiotto, S., Tetta, C., Brizzi, M. F., & Camussi, G. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.001 · Cited by 243
Interplay between miRNAs and host genes and their role in cancer
Liu, B., Shyr, Y., Cai, J., & Liu, Q. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz002 · Cited by 137
MicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
Neaga, A., Bagacean, C., Tempescul, A., Jimbu, L., Mesaros, O., Blag, C., Tomuleasa, C., Bocsan, C., Gaman, M., & Zdrenghea, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582915 · Cited by 30
Metadata
- Authors
- GAMBARI, R., BROGNARA, E., SPANDIDOS, D. A., & FABBRI, E.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2016-05-04
- Volume
- 49
- Issue
- 1
- Pages
- 5-32
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2345940501
- Cited by
- 262
- References
- 359
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: New trends in the development of miRNA therapeutic strategies in oncology (Review). https://app.cochat.ai/papers/10.3892/ijo.2016.3503
- The paper
- GAMBARI, R., BROGNARA, E., SPANDIDOS, D. A., & FABBRI, E. (2016). Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: New trends in the development of miRNA therapeutic strategies in oncology (Review). International Journal of Oncology. https://doi.org/10.3892/ijo.2016.3503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.